Liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12-and 18-month survival rates from the phase 3 NAPOLI 3 trial
Authors
O'Reilly, E. M.Melisi, D.
Macarulla, T.
Roberto, A.
Cid, P.
Chandana, S. R.
De La Fouchardiere, C.
Dean, A. P.
Kiss, I.
Lee, W. J.
Goetze, T. O.
Van Cutsem, E.
Paulson, S.
Bekaii-Saab, T. S.
Pant, S.
Hubner, Richard A
Xiao, Z. M.
Chen, H. Y.
Benzaghou, F.
Wainberg, Z. A.
Affiliation
Memorial Sloan Kettering Cancer Center, New York, NYIssue Date
2023
Metadata
Show full item recordCitation
O'Reilly EM, Melisi D, Macarulla T, Roberto A, Cid P, Chandana SR, et al. Liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12-and 18-month survival rates from the phase 3 NAPOLI 3 trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772000831.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.4006Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.4006Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.4006